Skip to main content
. 2013 Mar 21;8(3):e59726. doi: 10.1371/journal.pone.0059726

Figure 4. The PPARβ/δ antagonist GSK0660 blocks the catabolic effects of dexamethasone in cultured L6 myotubes.

Figure 4

A) PPARβ/δ activity in myotubes treated with or without 1 µM dexamethasone in the absence or presence of 0.1 µM GSK0660. B) FOXO1 protein levels in myotubes treated as described in panel A. FOXO1 levels were determined by Western blotting of nuclear extracts and A/C lamin levels were determined as loading controls. C) FOXO1 activity in myotubes treated for 24 h with 1 µM dexamethasone in the absence or presence of 0.1 µM GSK0660. D) Atrogin-1 and E) MuRF1 mRNA levels in myotubes treated for 24 h with or without 1 µM dexamethasone in the absence or presence of 0.1 µM GSK0660. F) Protein degradation (% per 24 h) in myotubes treated for 24 h with or without 1 µM dexamethasone in the absence or presence of 0.1 µM GSK0660. G) Diameter of myotubes after treatment for 24 h with or without 1 µM dexamethasone in the absence or presence of 0.1 µM GSK0660. Results are means ± SEM with n = 7 or 8/group. *p<0.05 vs Ctr/Veh by ANOVA.